Assessment of Human SARS CoV-2-Specific T-Cell Responses Elicited In Vitro by New Computationally Designed mRNA Immunogens (COVARNA)
暂无分享,去创建一个
J. Gelpí | M. Plana | Francisco Martínez-Jiménez | K. Breckpot | C. E. Gómez | L. Leal | Arthur Esprit | Lorenzo Franceschini | Lorena Usero | I. Esteban | Carmen Pastor-Quiñones | Marta Sisteré-Oró | Kris Thielemans | Andreas Meyerhans | Elena Aurrecoechea | Núria López-Bigas | Mariano Esteban | María José Alonso | Felipe García
[1] P. Stefanelli,et al. Omicron variant evolution on vaccines and monoclonal antibodies , 2023, Inflammopharmacology.
[2] D. Lye,et al. Comparative effectiveness of 3 or 4 doses of mRNA and inactivated whole-virus vaccines against COVID-19 infection, hospitalization and severe outcomes among elderly in Singapore , 2022, The Lancet Regional Health - Western Pacific.
[3] A. Bertoletti,et al. A comparative characterization of SARS-CoV-2-specific T cells induced by mRNA or inactive virus COVID-19 vaccines , 2022, Cell Reports Medicine.
[4] A. Bertoletti,et al. SARS-CoV-2-specific T cells in the changing landscape of the COVID-19 pandemic , 2022, Immunity.
[5] M. Verdonck,et al. A synthetic DNA template for fast manufacturing of versatile single epitope mRNA , 2022, Molecular therapy. Nucleic acids.
[6] J. Sullivan,et al. Vaccine-induced systemic and mucosal T cell immunity to SARS-CoV-2 viral variants , 2022, Proceedings of the National Academy of Sciences of the United States of America.
[7] A. Sette,et al. NVX-CoV2373 vaccination induces functional SARS-CoV-2–specific CD4+ and CD8+ T cell responses , 2022, bioRxiv.
[8] Christian A. Choe,et al. Combinatorial optimization of mRNA structure, stability, and translation for RNA-based therapeutics , 2022, Nature Communications.
[9] K. Kedzierska,et al. Count on us: T cells in SARS-CoV-2 infection and vaccination , 2022, Cell Reports Medicine.
[10] Irena Vlatkovic,et al. COVID-19 mRNA vaccines: Platforms and current developments , 2022, Molecular Therapy.
[11] P. Sopp,et al. An immunodominant NP105–113-B*07:02 cytotoxic T cell response controls viral replication and is associated with less severe COVID-19 disease , 2021, Nature Immunology.
[12] Aaron M. Rosenfeld,et al. Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses , 2021, Immunity.
[13] Y. Kreiss,et al. Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months , 2021, The New England journal of medicine.
[14] A. Sette,et al. Low-dose mRNA-1273 COVID-19 vaccine generates durable memory enhanced by cross-reactive T cells , 2021, Science.
[15] D. Weissman,et al. mRNA vaccines for infectious diseases: principles, delivery and clinical translation , 2021, Nature Reviews Drug Discovery.
[16] J. Mascola,et al. Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants , 2021, Science.
[17] M. Beltramello,et al. SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape , 2021, Nature.
[18] P. Dormitzer,et al. BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans , 2021, Nature.
[19] R. Xu,et al. mRNA vaccines for COVID-19: what, why and how , 2021, International journal of biological sciences.
[20] Yonghong Tang,et al. Exposure to SARS-CoV-2 generates T-cell memory in the absence of a detectable viral infection , 2021, Nature Communications.
[21] Felipe García,et al. In the Era of mRNA Vaccines, Is There Any Hope for HIV Functional Cure? , 2021, Viruses.
[22] Charles Y. Tan,et al. BNT162b vaccines protect rhesus macaques from SARS-CoV-2 , 2021, Nature.
[23] D. Lauffenburger,et al. Correlates of Protection Against SARS-CoV-2 in Rhesus Macaques , 2020, Nature.
[24] G. MacBeath,et al. Unbiased Screens Show CD8+ T Cells of COVID-19 Patients Recognize Shared Epitopes in SARS-CoV-2 that Largely Reside outside the Spike Protein , 2020, Immunity.
[25] Rebecca J. Loomis,et al. SARS-CoV-2 mRNA Vaccine Design Enabled by Prototype Pathogen Preparedness , 2020, Nature.
[26] Morten Nielsen,et al. Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19 , 2020, Cell.
[27] J. Greenbaum,et al. Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals , 2020, Cell.
[28] G. Kroemer,et al. Coronavirus infections: Epidemiological, clinical and immunological features and hypotheses , 2020, Cell stress.
[29] Hideo Baba,et al. CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation - A target for novel cancer therapy. , 2018, Cancer treatment reviews.
[30] Felipe García,et al. Loading dendritic cells with gold nanoparticles (GNPs) bearing HIV-peptides and mannosides enhance HIV-specific T cell responses. , 2018, Nanomedicine : nanotechnology, biology, and medicine.
[31] C. Brander,et al. Preclinical evaluation of an mRNA HIV vaccine combining rationally selected antigenic sequences and adjuvant signals (HTI-TriMix) , 2016, AIDS.
[32] O. Boyman,et al. Interleukin-2: Biology, Design and Application. , 2015, Trends in immunology.
[33] B. Neyns,et al. A phase IB study on intravenous synthetic mRNA electroporated dendritic cell immunotherapy in pretreated advanced melanoma patients. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[34] P. Eilers,et al. A phase I/IIa immunotherapy trial of HIV-1-infected patients with Tat, Rev and Nef expressing dendritic cells followed by treatment interruption. , 2012, Clinical immunology.
[35] J. Aerts,et al. Lumenal part of the DC-LAMP protein is not required for induction of antigen-specific T cell responses by means of antigen-DC-LAMP messenger RNA-electroporated dendritic cells. , 2010, Human gene therapy.
[36] T. Malek,et al. The biology of interleukin-2. , 2008, Annual review of immunology.
[37] Houping Ni,et al. Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. , 2005, Immunity.
[38] F. Brasseur,et al. Messenger RNA-Electroporated Dendritic Cells Presenting MAGE-A3 Simultaneously in HLA Class I and Class II Molecules1 , 2004, The Journal of Immunology.
[39] M. Norcross,et al. Natural Truncation of the Chemokine MIP-1β/CCL4 Affects Receptor Specificity but Not Anti-HIV-1 Activity* , 2002, The Journal of Biological Chemistry.
[40] S. Arya,et al. Identification of RANTES, MIP-1α, and MIP-1β as the Major HIV-Suppressive Factors Produced by CD8+ T Cells , 1995, Science.